Key Takeaways Shares of Cerebras (CBRS) tumbled over 3% Tuesday following Freedom Capital’s initiation of coverage with a Hold rating. First-quarter revenue surged 92% year-over-year to reach
Shares of Cerebras Systems experienced a decline exceeding 3% during Tuesday’s session, continuing to trade significantly beneath the stock’s yearly peak. The downturn followed Freedom Capital analyst Paul Meeks’ decision to launch coverage on the artificial intelligence semiconductor manufacturer with a Hold recommendation and $209 price objective.
The equity has experienced considerable volatility throughout recent months. Following its Nasdaq listing on May 14 at $185 per share, shares initially rallied before entering a sustained downtrend. Last week saw the stock temporarily fall beneath its initial public offering price.
Meeks acknowledged he had little interest in Cerebras prior to the earnings-related selloff. However, the price correction altered his perspective, despite recognizing potential concerns overlooked by market participants.
Cerebras unveiled its inaugural earnings report as a publicly traded entity following market close on June 23. Top-line results expanded 92% compared to the prior-year period, reaching $193.4 million. The net loss improved to $14 million versus $23.9 million in the corresponding quarter last year.
Hardware segment revenue increased 60% to $111.6 million. Cloud operations and related services revenue skyrocketed 167% to $79.8 million. Both figures exceeded Wall Street projections.
The issue emerged from profitability margin projections. Gross margins had improved from 42.1% in the year-ago quarter to 46.5% in the most recent period. However, management guided for margins to contract to a range of 38% to 41% for the complete fiscal year.
Executives clarified the company opted to temporarily lease back computing systems from a current customer while expanding its proprietary data center infrastructure. The chief executive officer subsequently indicated investors misinterpreted the guidance, emphasizing the margin compression stemmed from that isolated strategic choice rather than fundamental business challenges.
Cerebras manufactures large-scale, wafer-sized inference processors requiring specialized thermal management systems. Due to their physical dimensions, the firm distributes them exclusively as integrated systems rather than individual components.
The organization has secured significant strategic relationships. A $20 billion multi-year agreement with OpenAI was finalized in December. Additionally, the company established a partnership with Amazon Web Services to integrate Amazon’s Trainium processor with Cerebras’ CS-3 platform within AWS infrastructure facilities.
The AWS collaboration isn’t anticipated to generate substantial revenue contributions until 2027. Currently, Cerebras relies on its established hardware sales and cloud service operations to achieve financial objectives.
For the upcoming quarter, Cerebras anticipates revenue will increase 88% to $194 million. Annual core revenue projections range from $855 million to $865 million, translating to roughly 69% expansion.
Meeks identified two primary business segments driving Cerebras forward. The first involves marketing CS-3 systems for rapid AI inference applications. The second centers on collaborating with hyperscale cloud providers to distribute inference workloads, utilizing competing GPUs for initial processing stages and Cerebras’ processors for decode operations.
He perceives greater long-term value creation potential in the latter business model. He also observed the recent price decline has eliminated substantial investment risk that existed previously.
Nevertheless, Meeks cautioned there’s no certainty the recent bottom of $161 will function as a durable support threshold. He maintains that should Cerebras achieve its plan to triple revenue in 2027, the stock could demonstrate considerably more appreciation potential than downside vulnerability.
Prior to Meeks’ Hold assessment, analyst sentiment on Cerebras remained unanimously bullish with a Strong Buy rating across all 10 covering analysts. The consensus price target of $299.30 indicates 44% potential appreciation from present valuation levels.
CBRS equity was changing hands near $214 during Tuesday’s session, retreating from a 52-week peak of $386.34 while remaining above the yearly low of $160.81.
The post Cerebras (CBRS) Stock Declines 3% Following Hold Rating Despite Strong Growth Metrics appeared first on Blockonomi.
